Bank Of New York Mellon Corp Oric Pharmaceuticals, Inc. Transaction History

Bank Of New York Mellon Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$2.41 - $5.89 $32,074 - $78,390	13,309 New	13,309 $78,000
Q2 2022 Aug 15, 2022	SELL	$2.7 - $7.07 $262,253 - $686,716	-97,131 Reduced 87.95%	13,309 $60,000
Q1 2022 May 11, 2022	SELL	$4.54 - $16.1 $10,210 - $36,208	-2,249 Reduced 2.0%	110,440 $590,000
Q4 2021 Feb 11, 2022	BUY	$12.01 - $20.3 $22,518 - $38,062	1,875 Added 1.69%	112,689 $1.66 Million
Q3 2021 Nov 12, 2021	BUY	$15.9 - $25.22 $461,020 - $731,253	28,995 Added 35.44%	110,814 $2.32 Million
Q2 2021 Aug 11, 2021	BUY	$17.37 - $25.34 $87,405 - $127,510	5,032 Added 6.55%	81,819 $1.45 Million
Q1 2021 May 13, 2021	BUY	$23.67 - $36.85 $72,335 - $112,613	3,056 Added 4.14%	76,787 $1.88 Million
Q4 2020 Feb 09, 2021	BUY	$20.32 - $39.8 $1.04 Million - $2.04 Million	51,147 Added 226.47%	73,731 $2.5 Million
Q3 2020 Nov 12, 2020	SELL	$19.5 - $31.26 $2,379 - $3,813	-122 Reduced 0.54%	22,584 $564,000
Q2 2020 Aug 12, 2020	BUY	$25.68 - $38.12 $583,090 - $865,552	22,706 New	22,706 $765,000

112

63.1M

Ticker ORIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,576,700
Market Cap $406M
Description
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.